Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

INTRODUCTION: Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy profile similar to DMF but with improved gastrointestinal (GI) tolerability and low (< 1%) treatment discontinuati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wray, Sibyl, Then Bergh, Florian, Wundes, Annette, Arnold, Douglas L., Drulovic, Jelena, Jasinska, Elzbieta, Bowen, James D., Negroski, Donald, Naismith, Robert T., Hunter, Samuel F., Gudesblatt, Mark, Chen, Hailu, Lyons, Jennifer, Shankar, Sai L., Kapadia, Shivani, Mendoza, Jason P., Singer, Barry A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870078/
https://www.ncbi.nlm.nih.gov/pubmed/35211872
http://dx.doi.org/10.1007/s12325-022-02068-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870078/
https://www.ncbi.nlm.nih.gov/pubmed/35211872
http://dx.doi.org/10.1007/s12325-022-02068-7

Ejemplares similares